RxDoctor Payments Data

Tammy Johnsen, NP

Nurse Practitioner · Waukesha, WINPI 1073713913

Payments from drug & device makers

$2,593in general payments, 2019–2025

Across 27 payments — averaging $96.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AstraZeneca$996
  • Amgen$279
  • Johnson & Johnson$124
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$89
  • Abbott$27
  • plus $37 from 2 others

What the payments were for

  • Travel & lodging$52420%
  • Food & beverage$1,76468%
  • Education$30512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,593 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$14,155
Medicare patients
99
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$42,860
JardianceEmpagliflozin11$8,489
FarxigaDapagliflozin Propanediol11$6,320
Metoprolol Succinate61$624
Ezetimibe17$548
ClopidogrelClopidogrel Bisulfate44$479
Spironolactone50$257
Rosuvastatin Calcium35$239
Furosemide46$230
Atorvastatin Calcium26$227
Valsartan12$204
Digoxin11$162
Amlodipine Besylate19$76
Carvedilol14$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$996$6,32011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Waukesha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →